Earth Science Tech Files Q3 2025 10-Q

TL;DR

Earth Science Tech filed its Q3 2025 10-Q. Check financials.

AI Summary

Earth Science Tech, Inc. filed its quarterly report for the period ending December 31, 2024. The company, formerly known as Ultimate Novelty Sports Inc., is based in Miami, Florida, and operates in the pharmaceutical preparations sector. The filing covers the third quarter of fiscal year 2025.

Why It Matters

This filing provides investors with an update on Earth Science Tech's financial performance and operational status for the third quarter of fiscal year 2025.

Risk Assessment

Risk Level: medium — The company has a history of name changes and operates in a regulated industry, which can present inherent risks.

Key Numbers

• Q3 2025 — Fiscal Quarter (Reporting period)
• 0331 — Fiscal Year End (Company's fiscal year end)

Key Players & Entities

• Earth Science Tech, Inc. (company) — Filer
• Ultimate Novelty Sports Inc. (company) — Former company name
• Miami, Florida (location) — Business address
• 20241231 (date) — Period of report
• 20250214 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock $0.001 par value ETST Over the Counter Bul

Filing Documents

• form10-q.htm (10-Q) — 665KB
• ex31-1.htm (EX-31.1) — 13KB
• ex31-2.htm (EX-31.2) — 13KB
• ex32-1.htm (EX-32.1) — 9KB
• ex32-2.htm (EX-32.2) — 6KB
• form10-q_003.jpg (GRAPHIC) — 7KB
• 0001493152-25-006830.txt ( ) — 4141KB
• etst-20241231.xsd (EX-101.SCH) — 36KB
• etst-20241231_cal.xml (EX-101.CAL) — 56KB
• etst-20241231_def.xml (EX-101.DEF) — 101KB
• etst-20241231_lab.xml (EX-101.LAB) — 264KB
• etst-20241231_pre.xml (EX-101.PRE) — 217KB
• form10-q_htm.xml (XML) — 523KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION ITEM 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) F-1 Consolidated Balance Sheets F-1 Consolidated Statements of Operations F-2 Consolidated Statements of Changes in Shareholders' Equity F-3 Consolidated Statements of Cash Flows F-5

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements F-6- F-18 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 3 ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 8 ITEM 4.

Controls and Procedures

Controls and Procedures 8

OTHER INFORMATION

PART II. OTHER INFORMATION ITEM 1.

Legal Proceedings

Legal Proceedings 9 ITEM 1A.

Risk Factors

Risk Factors 9 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 9 ITEM 3. Defaults Upon Senior Securities 9 ITEM 4. Mine Safety Disclosures 9 ITEM 5. Other Information 9 ITEM 6. Exhibits 10

SIGNATURES

SIGNATURES 11 2 PART I – FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS EARTH SCIENCE TECH, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (UNAUDITED) As of December 31, 2024 As of March 31, 2024 ASSETS Current Assets: Cash $ 522,239 $ 697,721 Accounts Receivable 164,221 235,423 Equity Investments at fair value 1,100,773 - Inventory 137,557 315,738 Deposits 32,608 9,352 Prepaid 47,967 - Total current assets 2,005,365 1,258,234 Non-Current Assets: Property and Equipment, net 1,123,243 135,352 Right of use asset, net 189,871 156,517 Goodwill 2,302,792 2,302,792 Intangible Assets, net 86,743 28,441 Total Assets $ 5,708,014 $ 3,881,336 LIABILITIES AND EQUITY Accounts payable $ 46,292 $ 530,724 Accrued expenses and other payable 1,394,754 854,719 Current portion of operating lease obligations 118,227 70,487 Current portion of loans and obligations 755,319 30,592 Total Current Liabilities 2,314,592 1,486,522 Long-Term Liabilities: Lease liability less current maturities 70,190 84,950 Equipment loans and obligations non-current 42,785 60,559 Total Liabilities 2,427,567 1,632,031 Commitment and Contingencies ( Note 12) - - Stockholders' Equity: Preferred stock, par value $ 0.001 per share, 1,000,000 shares authorized; 1,000,000 and 1,000,000 shares issued and outstanding as of December 31, 2024, and March 31, 2024, respectively 1,000 1,000 Common stock, par value $ 0.001 per share, 350,000,000 shares authorized; 302,664,571 and 309,981,819 shares issued and outstanding as of December 31, 2024, and March 31, 2024, respectively 302,665 309,982 Additional paid-in capital 30,550,825 31,593,399 Accumulated deficit ( 27,574,043 ) ( 29,655,076 ) Total stockholders' Equity 3,280,447 2,249,305 Total Liabilities and Equity $ 5,708,014 $ 3,881,336 The accompanying condensed notes are an integral part of these unaudited consolidated financial

financial statements should be read in conjunction with audited consolidated financial statements and notes

financial statements should be read in conjunction with audited consolidated financial statements and notes. Note 2 — Summary of Significant Accounting Policies Basis of presentation The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United These financial statements must be read in conjunction with audited consolidated financial statements and notes thereto which are included in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 for a broader discussion of the Company's business and risks inherent in such business. In the opinion of management, all adjustments considered for a fair presentation, consisting solely of normal and recurring adjustments have been made. The results of operations for the three and nine months ended December 31, 2024 are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending March 31, 2025. Principles of consolidation The accompanying consolidated financial statements include all the accounts of the Company and its wholly owned subsidiaries RxCompoundstore.com LLC, Peaks Curative, LLC ,ESF, Avenvi LLC, and Mister Meds, LLC. All intercompany transactions have been eliminated during consolidation. Use of estimates and assumptions The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas requiring significant estimates are impairment of goodwill, provision for taxation, accrued l

View Full Filing

View this 10-Q filing on SEC EDGAR